STAMBP and Hand-foot syndrome: As α-MSH and TGF-β1 treatments have a relatively low potential risk of triggering side-effects, a promising therapeutic strategy could be the localization of α-MSH and TGF-β1 upregulation to certain HFs via follicular-targeting liposomal drugs.